Clearblue Class Action Lawsuit: Menopause Test Misleading, Consumers Claim

Case Overview: A class action lawsuit claims the Clearblue Menopause Test is ineffective and misleads consumers about its ability to determine menopause stage.

Consumers Affected: Consumers in the United States who purchased the Clearblue Menopause Test.

Court: U.S. District Court for the Northern District of California

Procter & Gamble and its partner, SPD Swiss Precision Diagnostics, falsely markets their Clearblue Menopause Stage Indicator test as a reliable tool for determining a woman’s menopause stage, a new lawsuit alleges. 

According to the lawsuit, the test, which measures follicle-stimulating hormone (FSH) levels, is scientifically useless for identifying menopause because FSH levels fluctuate at all stages of life, making the $20–$30 product a waste of money for consumers seeking clarity about their health.

Clearblue Menopause Test Misleading, Lawsuit Claims

Cassandra Marshall and Raquel Riley, both California residents, filed the proposed class action lawsuit after purchasing the Clearblue Menopause Test in 2023. Marshall bought two packages from a Rite Aid in Marin County after seeing an ad claiming the test could determine menopause stage. 

Riley, meanwhile, purchased the test from a CVS in Fremont following a similar ad. Both women say the product’s packaging reinforced this misleading claim, influencing their decision to buy it, and the pair argue that had they known the test was ineffective, they would not have purchased it. 

FSH Levels Not a Reliable Indicator of Menopause

Clearblue claims its Menopause Test can classify users into one of four menopause stages—premenopause, early perimenopause, late perimenopause, or postmenopause—by analyzing FSH levels from urine samples. However, medical experts, including the FDA, say that FSH levels are not a reliable indicator of menopause.

FSH fluctuates unpredictably, making it an unreliable marker for determining menopause status, the lawsuit explains. Instead, experts agree that tracking menstrual cycle patterns is the only valid method for identifying menopause transitions. The FDA has even stated that at-home menopause tests do not actually detect menopause but only measure FSH, which naturally rises and falls.

The lawsuit also challenges Clearblue’s use of research from the Study of Women’s Health Across the Nation (SWAN) to lend credibility to its test. While SWAN did define menopause stages, it did so based on bleeding patterns—not FSH levels. The lawsuit argues that Clearblue misleadingly combines FSH data with SWAN’s framework to create a false sense of scientific legitimacy.

Procter & Gamble Faces Other Lawsuits Over Misleading Marketing

This isn’t the only lawsuit Procter & Gamble is facing over misleading marketing. The company has been accused of greenwashing with its Charmin toilet paper brand, allegedly misrepresenting its environmental sustainability while contributing to deforestation in Canada’s boreal forests. Additionally, the company has been sued over its ZzzQuil melatonin sleep aid, which plaintiffs claim falsely promises “natural” sleep assistance.

Even Mielle Organics, a brand owned by P&G, is under legal scrutiny, with consumers alleging that its popular Rosemary Mint Scalp & Strengthening Hair Oil causes hair loss instead of promoting hair growth.

In their lawsuit, Marshall and Riley want to represent anyone in the United States that purchased the Clearblue Menopause Test in their claims of violations of nationwide and California consumer protection laws. They are seeking damages, restitution, fees, costs, and interest.

Case Details

• Lawsuit: Marshall, et al. v. Procter & Gamble Company, et al.
• Case Number: 4:25-cv-00923-DMR
• Court: U.S. District Court for the Northern District of California

Plaintiffs' Attorneys

• Annick M. Persinger (Tycko & Zavareei LLP)
• Shana H. Khader, Allison W. Parr, and Gemma Seidita (Tycko & Zavareei LLP)

Have you used the Clearblue Menopause Test? Share your thoughts on this lawsuit in the comments below.